Tivic Health Systems Inc. announced advancements in their ongoing research on Entolimod, a potential radiation countermeasure, during the 2025 Military Health System Research Symposium (MHSRS) held in Kissimmee, Florida. The discussions, which have not yet been detailed in prior releases, centered around Entolimod's potential to protect military personnel from radiation exposure in the field. Tivic Health's representatives engaged with decision-makers from key US Government agencies, including the Biomedical Advanced Research and Development Authority and the Armed Forces Radiobiology Research Institute, to explore deployment pathways for Entolimod as a military countermeasure. The symposium provided a platform for Tivic to connect with military leaders, researchers, and funding organizations to further their mission of enhancing warfighter health and readiness.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250815269899) on August 15, 2025, and is solely responsible for the information contained therein.
